- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT00524459
Pegylated Liposomal Doxorubicin and Docetaxel in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery
Phase II Study of Neoadjuvant Pegylated Liposomal Doxorubicin and Docetaxel in Locally Advanced Operable Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giving them before surgery may kill more tumor cells.
PURPOSE: This phase II trial is studying the side effects of giving liposomal doxorubicin together with docetaxel before surgery and to see how well it works in treating women with locally advanced breast cancer that can be removed by surgery.
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
OBJECTIVES:
Primary
- To evaluate the rate of pathological complete response and clinical complete response in women with locally advanced breast cancer treated with pegylated doxorubicin hydrochloride liposome and docetaxel.
Secondary
- To assess the overall clinical local regional response in patients treated with this preoperative chemotherapy regimen.
- To evaluate the number of patients who would have required a mastectomy upfront but who underwent breast conservation therapy instead after neoadjuvant chemotherapy.
- To assess the safety, particularly with regard to neutropenia and cardiac toxicity, of pegylated doxorubicin hydrochloride liposome and docetaxel.
OUTLINE: This is a multicenter study.
Patients receive pegylated doxorubicin hydrochloride liposome IV over 90 minutes and docetaxel IV over 90 minutes on day 1. Patients receive pegylated filgrastim subcutaneously on days 2 or 3 post-chemotherapy in courses 1-5. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Within 8 weeks after completion of chemotherapy, patients undergo a lumpectomy or mastectomy to remove the tumor. Some patients may receive additional therapy after surgery, including hormonal therapy, chemotherapy, or radiotherapy.
After completion of study therapy, patients are followed periodically for up to 5 years.
Studietyp
Inskrivning (Faktisk)
Fas
- Fas 2
Kontakter och platser
Studieorter
-
-
New York
-
Buffalo, New York, Förenta staterna, 14263-0001
- Roswell Park Cancer Institute
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed breast cancer using core biopsies
- Locally advanced disease
- Resectable disease
- Fine needle aspiration cytology allowed and must demonstrate invasive adenocarcinoma
- No more than 8 weeks since initial cytologic or histologic diagnosis of breast cancer
Tumor must meet the following criteria:
- Palpable on clinical examination and confined to either the breast or to the breast and ipsilateral axilla
- Measured clinically as greater than 2 cm in size (T2)
Patients with skeletal pain are eligible if bone scan and/or roentgenological examination fail to disclose metastatic disease
- Suspicious findings must be confirmed as benign by x-ray, MRI scan, or biopsy
- Hormonal status not specified
PATIENT CHARACTERISTICS:
Inclusion criteria:
- Female
- Menopausal status not specified
- ECOG performance status 0-2
- Life expectancy ≥ 10 years
- Platelet count ≥ 100,000/mm³
- ANC ≥ 1,500/mm³
- Hemoglobin ≥ 9.0 g/dL
- Bilirubin normal
- AST or ALT normal
- Alkaline phosphatase normal
- Serum creatinine normal
- Negative pregnancy test
- Fertile patients must use effective contraception (e.g., abstinence, intrauterine device, barrier device with spermicide, or surgical sterilization) during and for 3 months after completion of study therapy
- Normal cardiac function by LVEF or MUGA scan
Patients with prior non-breast malignancies are eligible if they have been disease-free for ≥ 10 years
The following are allowed even if diagnosed within the past 10 years:
- Squamous or basal cell carcinoma of the skin that has been effectively treated
- Carcinoma in situ of the cervix that has been treated by operation only
- Lobular carcinoma in situ of the ipsilateral or contralateral breast treated by segmental resection only
Exclusion criteria:
- Pregnant or lactating women
- Male patients
- Hyperbilirubinemia
Female patients with 1 or more of the following conditions:
Ulceration, erythema, infiltration of the skin (complete fixation), or peau d'orange (edema) of any magnitude
- Tethering or dimpling of the skin or nipple inversion should not be interpreted as skin infiltration
- Ipsilateral lymph nodes that are clinically fixed to one another or to other structures (N2 disease)
- Bilateral malignancy or a mass in the opposite breast suspicious for malignancy, unless there is biopsy proof that the mass is not malignant
- Suspicious palpable nodes in the contralateral axilla or palpable supraclavicular or infraclavicular nodes, unless there is biopsy evidence that these are not involved with the tumor
- Nonmalignant systemic disease (e.g., cardiovascular, renal, or hepatic) that would preclude study therapy
Active cardiac disease that would preclude the use of doxorubicin hydrochloride, including any of the following:
- Documented myocardial infarction
- Angina pectoris that requires the use of antianginal medication
- History of documented New York Heart Association class II-IV heart failure
- Valvular disease with documented cardiac function compromise
Poorly controlled hypertension (i.e., diastolic BP > 100 mm Hg)
- Patients with well-controlled hypertension and on medication are eligible for study
- Psychiatric or addictive disorders that would preclude obtaining informed consent
PRIOR CONCURRENT THERAPY:
Inclusion criteria:
- Concurrent noncancer therapies allowed if used for conditions other than breast cancer
- Adjuvant therapy after surgery allowed
Exclusion criteria:
- Prior radiotherapy, chemotherapy, immunotherapy, and/or hormonal therapy for breast cancer
- Prior anthracycline therapy for any condition
- Concurrent hormonal therapy including tamoxifen, aromatase inhibitors, or raloxifene
- Concurrent sex hormonal therapy including birth-control pills or ovarian hormonal replacement therapy
- Concurrent other cancer therapy
- Concurrent herbal or alternative therapies for breast cancer
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Enskild gruppuppgift
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
---|---|
Pathological Complete Response
Tidsram: Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Clinical Complete Response
Tidsram: Surgery done after completion of six cycles of study chemotherapy treatment.
|
Surgery done after completion of six cycles of study chemotherapy treatment.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Overall Clinical Local Regional Response
Tidsram: Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Mammogram done pre-treatment and after four and six cycles of study chemotherapy treatment.
|
Number of Women Who Would Have Required a Mastectomy Upfront But Who Underwent Breast Conservation Therapy Instead After Neoadjuvant Chemotherapy
Tidsram: Baseline (pre-treatment) surgical assessment, and post-chemotherapy surgical outcome.
|
Baseline (pre-treatment) surgical assessment, and post-chemotherapy surgical outcome.
|
Safety, in Terms of Neutropenia and Cardiac Toxicity
Tidsram: Every cycle during study treatment and 8 weeks post-treatment.
|
Every cycle during study treatment and 8 weeks post-treatment.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Tracey O'Connor, MD, Roswell Park Cancer Institute
Studieavstämningsdatum
Studera stora datum
Studiestart
Primärt slutförande (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Hudsjukdomar
- Neoplasmer
- Neoplasmer efter plats
- Bröstsjukdomar
- Bröstneoplasmer
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Tubulin modulatorer
- Antimitotiska medel
- Mitosmodulatorer
- Topoisomeras II-hämmare
- Topoisomerasinhibitorer
- Antibiotika, antineoplastiska
- Docetaxel
- Doxorubicin
- Liposomal doxorubicin
Andra studie-ID-nummer
- I 75506
- RPCI-I-75506
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstcancer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
Kliniska prövningar på docetaxel
-
Nereus Pharmaceuticals, Inc.AvslutadCancerFörenta staterna, Australien, Indien, Chile, Brasilien, Argentina
-
Tianjin Medical University Cancer Institute and...Rekrytering
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical... och andra samarbetspartnersOkänd
-
Zhuhai Beihai Biotech Co., LtdAvslutadFasta tumörer | Bioekvivalens | DocetaxelIndien
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaAvslutadIcke-småcellig lungcancer (NSCLC)Kina
-
Optimal Health ResearchAvslutadBröstcancer | Lungcancer | ProstatacancerFörenta staterna
-
Arog Pharmaceuticals, Inc.IndragenKarcinom, icke-småcellig lunga
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRekryteringKastrationsresistent prostatacancerAustralien
-
SanofiAvslutadNeoplasmer i huvud och halsFrankrike
-
SanofiAvslutadLungneoplasmerFrankrike, Nederländerna, Spanien, Kalkon, Belgien, Finland, Italien, Storbritannien